

Optimising and reviewing Proton Pump Inhibitors (PPIs)

Background information and adverse effects

PPIs are widely prescribed and the benefits of using them for treating several upper GI conditions and for gastroprotection are well known, with adverse effects such as headache, nausea and diarrhoea, usually being mild and reversible. However, there are concerns regarding the long-term risks of PPIs. Several observational studies have associated long-term use of PPIs with risks of several serious adverse effects.

NICE CKS information on proton pump inhibitors states that long-term treatment may be associated with uncommon, serious adverse effects such as *Clostridioides difficile* infections, increased risk of bone fractures in susceptible populations, hypomagnesaemia and rebound acid hypersecretion syndrome. Rare or very rare adverse effects of PPIs are listed to include subacute cutaneous lupus erythematosus and tubulointerstitial nephritis and the British Society of Gastroenterology suggest an increased risk of spontaneous bacterial peritonitis in cirrhotic patients. Please see the BNF or the product's SPC for the full list of side effects. Therefore, clinical judgement should be used on an individual basis to assess the risks and benefits of long-term PPI use and included in shared decision-making discussions, with the lowest effective dose continued where appropriate.

Lifestyle measures

Some lifestyle measures may help improve symptoms for conditions such as dyspepsia and/or reduce the risk of gastrointestinal bleeding. These include:

- Weight loss if overweight or obese
- Avoiding trigger foods and drinks. These could include rich, spicy, or fatty foods, coffee, cola and chocolate.
- Eating smaller, regular meals and not eating 3-4 hours before going to bed, where possible.
- Stopping smoking.
- Reducing alcohol consumption to within recommended limits.
- Manage stress and anxiety.


Interactions:

See BNF/SPC for list of drug interactions.

Conflicting evidence for the interaction between omeprazole/esomeprazole and clopidogrel (see [MHRA alert](#) for more detail)

Medication review recommendations

- Review other medication for which may possibly cause or exaggerate dyspepsia, considering stopping or reducing if possible and appropriate. These include alpha-blockers, anticholinergics, calcium-channel blockers, corticosteroids, nitrates, non-steroidal anti-inflammatories (NSAIDs), theophylline and tricyclic antidepressants.
- Offer annual reviews, or more often if appropriate, to those needing long term management of dyspepsia.
- Review long-term PPI usage at least annually conducting a risk vs benefit review of PPI, exercising caution in those patients with other risk factors for bone fractures and/or *Clostridioides difficile* infection.
- If a medication that increases bleed risk is stopped, re-review the need for the PPI. E.g. if PPI used for NSAID gastroprotection, and no longer needing NSAID, stop PPI.
- Encourage patients to report side effects.
- If deciding to stop PPI/change to when required (PRN) use, advise patient of possible rebound acid hypersecretion. Advise gradual tapering over several weeks, using antacids if needed during this time.
- Consider adding indication to PPI directions. This may help decision-making when consider deprescribing e.g. on hospital admission.



Indication	Typical daily dose (See NICE CG184 for details, except where indicated)
Barrett's oesophagus	Omeprazole or Esomeprazole 20-40mg daily, or lansoprazole 30mg daily (titrate dose as needed to ensure no breakthrough symptoms) long-term.
Oesophageal strictures	Omeprazole 20-40mg, or Lansoprazole 15-30mg long term.
GORD/dyspepsia	Omeprazole 20-40mg or Lansoprazole 30mg for 4-8 weeks then review stopping (prescribe at lowest effective dose if required e.g. Omeprazole 10mg daily).
Oesophagitis/Gastritis	Omeprazole 20-40mg or Lansoprazole 30mg for 8 weeks to aid healing (maybe required long-term). Use omeprazole 40mg BD or Esomeprazole 20-40mg for endoscopically proven severe oesophagitis (LA grade C/D) or if refractory to initial treatment.
Ulcers (duodenal, gastric, NSAID associated)	Omeprazole 40mg or Lansoprazole 30mg for 4-8 weeks (long-term if NSAID continuing) then review. Consider re-scoping. If symptoms recur, restart PPI at the lowest effective dose. Esomeprazole 40mg if previously on PPI.
Prophylaxis (see table below)	Omeprazole 10-20mg or Lansoprazole 15-30mg whilst taking the drug, stop the drug if possible. Note: medicines listed below are known to cause peptic ulceration/increase bleeding risk. Other medicines e.g. bisphosphonates can cause reflux.
H pylori treatment	Omeprazole 20-40mg twice daily for 7 days (in addition to H pylori eradication antibiotics).
Zollinger-Ellison Syndrome	Omeprazole 20-120mg or Lansoprazole 60-120mg in two divided doses (adjusted to response) long term.
Pancreatic enzyme replacement therapy	Omeprazole 20mg – 40mg twice daily dose. Twice daily dosing (morning and evening) with PPI is often recommended to optimise therapy over a 24-hour period (See UBHW PERT clinical guideline)

***High risk patients - When to consider co-prescribing gastroprotection:**

NSAIDs, antiplatelets, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors are the main medications associated with GI bleed risk. Individual additional patient risk factors will determine if gastroprotection may be required. *Please note this list is not exhaustive and a comprehensive review of all patient risk factors should be undertaken to help determine the patient's need for gastroprotection*


NSAIDs
Moderate and high-risk patients → Gastroprotection required
(Moderate/high risk are: 1-2 risk factors, or previous complicated ulcer, or elderly, or patients with osteoarthritis and rheumatoid arthritis)
Low-risk patients = No risk factors → Gastroprotection not required

What are the NSAID GI risk factors?
Patients aged over 65, high dose or prolonged use of NSAID, history of gastroduodenal ulcer/perforation or GI bleeding, significant comorbidity (e.g. cardiovascular disease, hepatic or renal impairment, diabetes, hypertension), heavy smoking, excessive alcohol consumption, previous adverse reaction to NSAIDs, concomitant use of medications that are known to increase likelihood of upper GI bleeds, chronic low back pain/axial spondyloarthritis, psoriatic arthritis, peripheral spondyloarthritis.

Antiplatelets
Gastroprotection should be considered alongside antiplatelets in patients: Taking high-dose aspirin, taking clopidogrel, who are elderly, history of gastroduodenal ulcer/perforation or GI bleeding, have a H.Pylori infection, taking concomitant use of medication with GI bleed risk (see list above)

Anticoagulation, corticosteroids, selective serotonin reuptake inhibitors:
Gastroprotection should be considered alongside these medications in patients with: History of gastroduodenal ulcer/perforation or GI bleeding, concomitant use of medication with GI bleed risk (see list above), older age, serious comorbidity (e.g. advanced cancer)

Patients admitted to hospital



References

NICE CG184, 2019. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. Available from www.nice.org.uk/guidance/cg184
 NBT Antibiotic guidelines, 2023. Available via NBT intranet and Microguide, V7.3.
 MHRA, 2014. [Clpidogrel and proton pump inhibitors: interaction – updated advice - GOV.UK \(www.gov.uk\)](https://www.prescqipp.info/umbraco/surface/authorisedmediasurface/index?url=%2fmedia%2f5085%2f267-ppis-long-term-safety-and-gastroprotection-1807)
 Proton Pump Inhibitors (PPIs): Long term safety and gastroprotection. PrescQIPP Bulletin 267 (2). Last revised August 2020. Available from <https://www.prescqipp.info/umbraco/surface/authorisedmediasurface/index?url=%2fmedia%2f5085%2f267-ppis-long-term-safety-and-gastroprotection-1807>
 NICE CKS, May 2023. NSAIDs - prescribing issues. Available from: <https://cks.nice.org.uk/topics/nsaids-prescribing-issues/>

UBHW Pancreatic enzyme replacement therapy clinical guideline V3.0. October 2021. Available from UBHW intranet
 Guidelines on the management of ascites in cirrhosis. Aithal, p., et al, 2020. British Society of Gastroenterology. Available from: <https://www.bsg.org.uk/clinical-resource/guidelines-on-the-management-of-ascites-in-cirrhosis/>
 Adapted from: Farrell, B., Pottie, K., Thompson, W., Boghossian, T., Pizzola, L., Rashid, F.J., et al, 2017. Deprescribing PPIs. Evidence-based clinical practice guideline. www.deprescribing.org.
 NICE CKS, July 2023. Dyspepsia – unidentified cause. Available from <https://cks.nice.org.uk/topics/dyspepsia-unidentified-cause/>
 NICE CKS, July 2023. Prescribing information for proton pump inhibitors. Available from: <https://cks.nice.org.uk/topics/dyspepsia-proven-gord/prescribing-information/proton-pump-inhibitors/>